{
    "pmcid": "9082315",
    "qa_pairs": {
        "How did the study enhance the therapeutic potential of the nanobodies?": [
            "By fusing them to the Fc region of human IgG1",
            "By increasing their molecular weight",
            "By modifying their amino acid sequences",
            "By combining them with antiviral drugs"
        ],
        "What animal was used to generate the panel of nanobodies targeting the SARS-CoV-2 spike protein RBD?": [
            "Dromedary camels",
            "Llamas",
            "Alpacas",
            "Mice"
        ],
        "What technique was used to identify the specific binding epitopes of the nanobodies?": [
            "Cryo-electron microscopy",
            "X-ray crystallography",
            "Nuclear magnetic resonance (NMR) spectroscopy",
            "Surface plasmon resonance (SPR)"
        ],
        "What was the outcome of in vivo studies using potent neutralizing hcAbs in hACE2-transgenic mice?": [
            "Prevention of lethal SARS-CoV-2 infection",
            "Partial reduction in viral load",
            "No significant effect on infection",
            "Increased susceptibility to infection"
        ],
        "What was the primary reason the engineered heavy chain antibodies were ineffective against the Omicron variant?": [
            "Extensive mutations in the RBD overlapping with Nb binding sites",
            "Lack of binding to the spike protein",
            "Inability to block ACE2 receptor binding",
            "Low binding affinity to the RBD"
        ]
    }
}